Instrument NameAbcellera Biologics IncInstrument Symbol(ABCL-Q)

Instrument ExchangeNASDAQ

ABCL earnings call for the period ending March 31, 2023.

AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

Check out these compelling opportunities.

Abdera is developing sophisticated antibodies that can deliver radiopharmaceutical therapies to specific cancer cells like a parcel delivery service

AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being held at the Orange County Convention Center...

These companies are leading the way in using AI in healthcare.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, April 25, 2023, at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time).

AbCellera (Nasdaq: ABCL) will announce its first quarter 2023 financial results on Thursday, May 4, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and...

AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held at the Orange County Convention Center in Orlando,...